Laurel Wealth Advisors (North Carolina)’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-569
Closed -$17.8K – 593
2025
Q4
$17.8K Buy
+569
New +$14K ﹤0.01% 430
2025
Q2
– Sell
-569
Closed -$8.75K – 612
2025
Q1
$8.75K Hold
569
– – ﹤0.01% 487
2024
Q4
$12.5K Hold
569
– – ﹤0.01% 466
2024
Q3
$10.3K Buy
569
+333
+141% +$5.83K ﹤0.01% 459
2024
Q2
$3.83K Buy
+236
New +$3.63K ﹤0.01% 510

Other funds holding TEVA

Laurel Wealth Advisors (North Carolina)'s TEVA Position: Q1 2026 in Review

Laurel Wealth Advisors (North Carolina) sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2026, closing a stake of 569 shares — an estimated $17.8K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in TEVA in Q2 2024 and held it in 5 quarters. The position peaked at $17.8K in Q4 2025. 654 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2026 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 569 Teva Pharmaceutical Industries Limited shares in Q1 2026, an estimated $17.8K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Teva Pharmaceutical Industries Limited in Q2 2024 and held it in 5 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Teva Pharmaceutical Industries Limited position peaked at $17.8K in Q4 2025.
  • 654 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2026.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2026, filed 13 May 2026.